0000899243-19-028027.txt : 20191122 0000899243-19-028027.hdr.sgml : 20191122 20191122210022 ACCESSION NUMBER: 0000899243-19-028027 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191121 FILED AS OF DATE: 20191122 DATE AS OF CHANGE: 20191122 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Siu Christine CENTRAL INDEX KEY: 0001743029 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38533 FILM NUMBER: 191243212 MAIL ADDRESS: STREET 1: C/O EIDOS THERAPEUTICS, INC. STREET 2: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94101 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Eidos Therapeutics, Inc. CENTRAL INDEX KEY: 0001731831 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463733671 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 650-391-9740 MAIL ADDRESS: STREET 1: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-11-21 0 0001731831 Eidos Therapeutics, Inc. EIDX 0001743029 Siu Christine C/O EIDOS THERAPEUTICS, INC. 101 MONTGOMERY STREET, SUITE 2000 SAN FRANCISCO CA 94104 0 1 0 0 CFO and Secretary Common Stock 2019-11-21 4 M 0 25000 0.59 A 61470 D Common Stock 2019-11-21 4 S 0 24800 55.116 D 36670 D Common Stock 2019-11-21 4 S 0 200 56.00 D 36470 D Common Stock 2019-11-22 4 M 0 10000 0.59 A 46470 D Common Stock 2019-11-22 4 S 0 9399 54.7105 D 37071 D Common Stock 2019-11-22 4 S 0 601 55.2949 D 36470 D Stock Option (right to buy) 0.59 2019-11-21 4 M 0 25000 0.00 D 2027-12-21 Common Stock 25000 192191 D Stock Option (right to buy) 0.59 2019-11-21 4 M 0 10000 0.00 D 2027-12-21 Common Stock 10000 182191 D Represents the weighted average sale price of the shares sold from $55.00 to $55.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Represents the weighted average sale price of the shares sold from $54.21 to $55.19 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Represents the weighted average sale price of the shares sold from $55.21 to $55.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. The shares subject to this option vest and become exercisable in 48 equal monthly installments after December 1, 2017, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. /s/ Franco Valle, as Attorney-in-Fact 2019-11-22